California Department of Public Health STATEMENT OF DEFICIENCIES (X3) DATE SURVEY (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION AND PLAN OF CORRECTION COMPLETED IDENTIFICATION NUMBER A BUILDING B WING CA140000034 10/14/2009 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE 1411 E 31ST ST ALAMEDA COUNTY MEDICAL CENTER OAKLAND, CA 94602 SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION (X4) ID ID (X5) (EACH DEFICIENCY MUST BE PRECEDED BY FULL PREFIX (EACH CORRECTIVE ACTION SHOULD BE COMPLETE PREFIX REGULATORY OR LSC IDENTIFYING INFORMATION) DATE CROSS-REFERENCED TO THE APPROPRIATE TAG TAG DEFICIENCY) E 000 E 000 Initial Comments RECEIVED The following reflects the findings of the California Department of Public Health during the FEB 01 2010 investigation of an entity reported incident. Licensing & Certification ENTITY REPORTED INCIDENT NUMBER: East Bay District Office CA00204680 Representing the Department: RN, HFEN and Pharmaceutical Consultant, II The inspection was limited to the specific entity reported incident investigated and does not represent the findings of a full inspection of the facility. E 264 T22 DIV5 CH1 ART3-70213(a) E 264 E 264 T22 DIV5 CH1 ART3-70213(a) Nursing Service Nursing Services Policies and Procedures Policies and Procedures. E 474 T22 DIV5 CH1 ART3-70263(c) Pharmaceutical Service General (a) Written policies and procedures for patient Requirements care shall be developed, maintained and E 475 T22 DIV5 CH1 ART3-70263(c)(1) implemented by the nursing service. Pharmaceutical Service General Requirement E 483 T22 DIV5 CH1 ART3-70263(g) This Statute is not met as evidenced by: Pharmaceutical Service General Requirement E 485 T22 DIV5 CH1 ART3-70263(g)(2) E 474 T22 DIV5 CH1 ART3-70263(c) Pharmaceutical E 474 Pharmaceutical Service General Service General Requirements Requirements The Hospital failed to ensure policies and procedures related to medication distribution (c) A pharmacy and therapeutics committee, or a committee of equivalent composition, shall be and medication administration were established. The committee shall consist of at implemented and the Dilantin was administered as ordered. Patient received least one physician, one pharmacist, the director of nursing service or her representative and the one gram of Dilantin IVP (intravenous push) administrator or his representative. within five minutes that should have been given slowly over an hour as ordered by the physician. The medication error resulted in

Licensing and Certification Division

critte LABORATORY DIRECTORS OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE

TITLE

STATE FORM

MOV011

Marking T/8/10

California	a Department of Put	olic Health							
AND PLAN OF CORRECTION IDEN		IDENTIFICATION NU	PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER.		TIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED			
		CA140000034			~~~~	10/14/2009			
TVIIIE OF THOUSER ON CONTENENT					DRESS, CITY, STATE, ZIP CODE				
ALAMED	A COUNTY MEDICAL	L CENTER	1411 E 31 OAKLANI	ST ST D, CA 9460	2				
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)			ID PREFIX TAG	PROVIDER'S PLAN OF CORREC (EACH CORRECTIVE ACTION SHO CROSS-REFERENCED TO THE APPR DEFICIENCY)	OULD BE COMPLET			
E 474	Continued From page 1			E 474	the rapid deterioration and death of patient. Corrective Action: 1. All ICU RN staff were re-educated on the Medication Administration policy and procedures. 2. All ICU RN's were educated on Transcribing Medication physician orders. 3. All pharmacists were in-serviced to provide drug, dosage route and rate of administration when any nursing staff calls pharmacy requesting information regarding medications. 4. All ICU staff were re-educated regarding Dilantin, the indications, the route, dosage and rate of administration for a loading dose. 5. Pharmacy added Dilantin to the High Risk Medications policy and re-educated the nursing staff regarding Dilantin and				
	This Statute is not met as evidenced by:								
E 475	T22 DIV5 CH1 ART3-70263(c)(1) Pharmaceutical Service General Requirements			E 475					
	(1) The committee shall develop written policies and procedures for establishment of safe and effective systems for procurement, storage, distribution, dispensing and use of drugs and chemicals. The pharmacist in consultation with other appropriate health professionals and administration shall be responsible for the development and implementations of procedures. Policies shall be approved by the governing body. Procedures shall be approved by the administration and medical staff where such is appropriate.								
	This Statute is not met as evidenced by:				High Risk medications. 6. All Dilantin was removed from pyxis machines immediately up notification of the event.	ACMC			
	T22 DIV5 CH1 ART3-70263(g) Pharmaceutical Service General Requirements			E 483	7. Pharmacists will now mix all D and label with drug name, dose, and administration rate.				
	(g) No drugs shall be administered except by licensed personnel authorized to administer drugs and upon the order of a person lawfully authorized to prescribe or furnish. This shall not preclude the administration of aerosol drugs by respiratory therapists. The order shall include the name of the drug, the dosage and the frequency of administration, the route of administration, if other than oral, and the date, time and signature of the prescriber or furnisher. Orders for drugs should be written or transmitted by the prescriber or furnisher. Verhal orders for drugs shall be				 Additional ICU competencies he developed specifically addressing risk alert medications and medical administration which will now many RN working in ICU to take cognitive test. The electronic time of the scanner pharmacy orders on this patient reviewed to identify any process system errors. ICU orders were to pharmacy at 1446 and medical 	ng high cation require written ned were s and s scanned			

California	a Department of Pul	olic Health					01/13/201 APPROVE
AND PLAN OF CORRECTION IDENTIFICATION		(X1) PROVIDER/SUPPLIE IDENTIFICATION NUI			NG	(X3) DATE SURVEY COMPLETED C 10/14/2009	
NAME OF P	ROVIDER OR SUPPLIER		STREET AD	DRESS, CITY	STATE, ZIP CODE		
ALAMED	A COUNTY MEDICAL	L CENTER	1411 E 31 OAKLANI	IST ST D, CA 9460:	2		
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)			ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (X5) (EACH CORRECTIVE ACTION SHOULD BE COMPLE CROSS-REFERENCED TO THE APPROPRIATE DATE DEFICIENCY)		
	prescribe or furnish promptly in the pati the name of the pe and the signature order. The prescrib countersign the order. This Statute is not	son lawfully authorized and shall be recorded ent's medical record, rson giving the verbal of the individual receiver or furnisher shall ler within 48 hours. The met as evidenced by the son lawful and evidenced by the son lawful and the son	ed noting I order ving the	E 483	administered at 2155. It was in that the order written at 1400 vereviewed by pharmacy since E was in the Pyxis and assumed pharmacy that Dilantin had alreadministered. This has been comby removing all Dilantin from and requiring pharmacy to predug for administration. 10. Nursing and Pharmacy developmonactive committee to review the medication process to iden process/system issues that wor patients at risk for medication. 11. ICU will implement 12 hour cleaces for nursing to check all for complete drug information.	was not Dilantin by ready been corrected the Pyxis pare the ped a and flow tify ald put event. hart MARs'	
	This Statute is not Based on staff inter hospital failed to en related to medicatic administration were was administered a one gram of Dilanti within five minutes slowly over an hour	met as evidenced by view and record reviews and record reviews and properties and properties and the implemented and the ist ordered. Patient 14 in IVP (intravenous puthat should have been as ordered by the phor resulted in the rapi	ews, the ocedures edication e Dilantin received ush) n given by sician.		includes drug, dose, route, and administration and compare the the physician's orders. 12. The RN who administered the placed on Do Not Return, the r who employees the RN was not CDPH, The Joint Commission California Board of Nursing w notified of the event. Completion Date: 1. 10/14/09 2. 10/14/09 3. 10/14/09 4. 10/14/09 5. 10/14/09 6. 10/14/09	rate of e MAR to drug was registry otified, the , and the	
		nmary dated 10/14/09			7. 10/14/09 8. 12/31/09 9. 10/14/09		

for sudden shortness of breath and chest pain.

Patient 14 had a history of hypertension and end stage renal disease. Patient 14 received dialysis

(process to remove chemicals and wastes from

10. 10/15/09

11. 10/14/09

12. 10/15/09

PRINTED: 01/13/2010 FORM APPROVED California Department of Public Health STATEMENT OF DEFICIENCIES (X3) DATE SURVEY (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION AND PLAN OF CORRECTION COMPLETED IDENTIFICATION NUMBER: A. BUILDING C B WING CA140000034 10/14/2009 STREET ADDRESS, CITY, STATE, ZIP CODE NAME OF PROVIDER OR SUPPLIER 1411 E 31ST ST ALAMEDA COUNTY MEDICAL CENTER OAKLAND, CA 94602 SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION (X4) ID (X5)PREFIX (EACH DEFICIENCY MUST BE PRECEDED BY FULL PREFIX (EACH CORRECTIVE ACTION SHOULD BE COMPLETE REGULATORY OR LSC IDENTIFYING INFORMATION) CROSS-REFERENCED TO THE APPROPRIATE DATE TAG TAG DEFICIENCY) E 485 E 485 Continued From page 3 Monitoring: 1. Nursing will review 30 charts per month the blood through a machine when the kidneys no longer function) three times a week on Mondays. to ensure that MAR's match the Wednesdays and Fridays. physician orders and have the drug. dosage, route and rate of administration The Progress Notes dated 10/7/09 showed that for every medication. while having hemodialysis, Patient 14 had 2. Daily nursing will review, during the 12 seizures, high blood pressure and developed hour chart check, all MARs for pulmonary edema (lung congestion) that required completeness with drug, dose, route, and intubation (insertion of breathing tube and rate of administration. connected to a respirator). Patient 14 was 3. The Director of Pharmacy will randomly transferred to the intensive care unit at 2:40 p.m. observe pharmacy providing drug information to ensure all elements, drug, The physician's orders dated 10/7/09 at 2 p.m. dose, route, and rate of administration. included a physician's order that specifically stated to check the patient's dilantin level first and Persons Responsible: to, "give 1 gm (gram) Dilantin over 1 hr (hour). IV Tina Bray, Director of Nursing (into the bloodstream through a vein access), Gurpreet Johal, Director of Pharmacy don't push quickly." A Consultation Report dated Linda Jenkins, CNE 10/7/08 at 3 p.m. indicated that Patient 14 was, Bill Manns, COO "Currently hemodynamically (pertains to blood Jeanette Cotanche, CQO circulation) stable." Review of the Medication Record showed a handwritten transcription of the order for Dilantin as, "Dilantin 1000 mg load." Dilantin was initialed and signed by RN Z as given on 10/7/09 at 9:55 p.m.. RN Z administered the Dilantin loading dose within five minutes IVP (manually and directly into the bloodstream through a vein

access).

The Progress Record dated 10/7/09 at 10:40 p.m. showed that at 10:01 p.m., (six minutes after Dilantin was given), Code Blue was called in the intensive care unit because Patient 14 had bradycardia (heart rate less than 60 per minute) with PEA (pulse less electrical activity of the heart). The resuscitation efforts failed. An ultrasound of Patient 14's heart taken at the bedside confirmed that Patient 14 did not have a

MOV011

FORM APPROVED California Department of Public Health (X3) DATE SURVEY STATEMENT OF DEFICIENCIES (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION AND PLAN OF CORRECTION COMPLETED IDENTIFICATION NUMBER A BUILDING C B WING CA140000034 10/14/2009 STREET ADDRESS, CITY, STATE, ZIP CODE NAME OF PROVIDER OR SUPPLIER 1411 E 31ST ST ALAMEDA COUNTY MEDICAL CENTER OAKLAND, CA 94602 SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION (X4) ID (X5)(EACH DEFICIENCY MUST BE PRECEDED BY FULL (EACH CORRECTIVE ACTION SHOULD BE COMPLETE PREFIX PRFFIX REGULATORY OR LSC IDENTIFYING INFORMATION) CROSS-REFERENCED TO THE APPROPRIATE DATE TAG TAG DEFICIENCY) E 485 E 485 Continued From page 4 cardiac tamponade (compression of the heart resulting from the accumulation of fluid within the heart sac) and that there was no heart activity. Patient 14 died at 10:24 p.m. Review of the hospital's written Medication Administration policy and procedure, revised on 2/09 showed that its purpose was to ensure safe administration of medications to patients. Medications are administered to patients by licensed and approved personnel that included registered nurses. The Medication Administration policy and procedure showed that all inpatient orders will be scanned to the Inpatient Pharmacy, reviewed by a pharmacist and entered into the Pharmacy Computer System that would generate a patient specific label. Pharmacy would prepare, check and match the medication with the associated label in preparation for delivery. The policy indicated that it would be the responsibility of the nurse to review the patient specific label for accuracy. The Medication Administration procedure required that before the administration of a medication, the registered nurse who would administer the medication would verify the medication based on the medication order and product label. The registered nurse would verify and be familiar that the medication be administered at the right dose, correct route and rate of administration. Review of a memorandum dated 10/8/09 showed that RN Z pushed one gram of Dilantin over five minutes, and the cardiac strips clearly indicate rhythm changes at that time. RN Z had said that

she clarified with the pharmacist how to give the

Dilantin and was told to "push" Dilantin.

California Department of Public Health STATEMENT OF DEFICIENCIES (X3) DATE SURVEY (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION COMPLETED AND PLAN OF CORRECTION IDENTIFICATION NUMBER: A BUILDING B WING CA140000034 10/14/2009 STREET ADDRESS, CITY STATE, ZIP CODE NAME OF PROVIDER OR SUPPLIER 1411 E 31ST ST ALAMEDA COUNTY MEDICAL CENTER OAKLAND, CA 94602 SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION (X4) ID 10 (X5) (EACH DEFICIENCY MUST BE PRECEDED BY FULL (EACH CORRECTIVE ACTION SHOULD BE COMPLETE PREFIX PRFFIX REGULATORY OR LSC IDENTIFYING INFORMATION) CROSS-REFERENCED TO THE APPROPRIATE DATE TAG TAG DEFICIENCY) E 485 E 485 Continued From page 5 The Lexi-Comp's Drug Information Handbook, 2009-2010 18th Edition listed that Dilantin is a drug to manage and prevent seizures. The warning and precautions with its use in IV form include hypotension and bradycardia. The adverse effects included, but not limited to hypotension, bradycardia, cardiac arrhythmias and cardiovascular collapse (especially with rapid IV use) The maximum rate of administration is 50 mg per minute. All loading doses of Dilantin should be administered in IVPB in saline. During an interview on 10/14/09 at 10:27 a.m. RN Z said, she called the pharmacy on 10/7/09 and requested the pharmacy to mix Dilantin. According to RN Z, the pharmacist instructed her to get four ampoules of Dilantin 250 mg from the Pyxis (a medication distribution system) and give the medication IV, without any recommendation on how to give it. RN Z said, "It shouldn't have happened, I shouldn't have listened to the pharmacist, and it didn't sound right to give four vials IV push. I should have refused." RN Z failed to review and follow the physician's order to give Dilantin over an hour. RN Z failed to recognize that the maximum rate of IV administration of dilantin was 50 mg per minute. During an interview on 10/14/09 at 12:10 p.m., Pharmacist A acknowledged she received a telephone call from RN Z and instructed RN Z to mix four ampoules of Dilantin 250 mg in a 250 ml bag of saline and use a .22 micron filter when administering the Dilantin. Pharmacist A failed to indicate the rate of administration she had instructed RN Z to give the total amount of Dilantin 1000 mg.

During an interview on 11/19/09 at 9:30 a.m., the Director of Pharmacy acknowledged that Dilantin

MOV011

PRINTED: 01/13/2010 FORM APPROVED California Department of Public Health STATEMENT OF DEFICIENCIES (X3) DATE SURVEY (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION AND PLAN OF CORRECTION COMPLETED IDENTIFICATION NUMBER: A BUILDING B WING CA140000034 10/14/2009 STREET ADDRESS, CITY, STATE, ZIP CODE NAME OF PROVIDER OR SUPPLIER 1411 E 31ST ST ALAMEDA COUNTY MEDICAL CENTER OAKLAND, CA 94602 SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION (X5) COMPLETE (X4) ID (EACH DEFICIENCY MUST BE PRECEDED BY FULL (EACH CORRECTIVE ACTION SHOULD BE PREFIX PREFIX DATE REGULATORY OR LSC IDENTIFYING INFORMATION) CROSS-REFERENCED TO THE APPROPRIATE TAG TAG DEFICIENCY) E 485 Continued From page 6 E 485 order for Patient 14 was not reviewed in advance of administration as required by the current policy and procedure on Medication Administration. There was no evidence that the pharmacy received and reviewed the scanned physician's order for Dilantin written on 10/7/09 at 2 p.m.. The nurse administered Dilantin 1000 mg on 10/7/09 at 9:55 p.m. within five minutes (rather than an hour). The hospital staff had approximately over seven hours to correctly process the Dilantin order to ensure the safe administration of the drug to Patient 14 and prevent the medication error. The facility's failure to ensure its medication distribution and administration policies were followed is a deficiency that has caused, or is likely to cause, serious injury or death to the patient, and therefore constitutes an immediate jeopardy within the meaning of Health and Safety Code section 1280.1(c).

MOV011